UNIVERSAL PROBE, PRIMER-PROBE SET AND KIT

Abstract

The present application relates to a field of a biological detection technology, in particular, relates to a universal probe, a primer-probe set and a kit. The present application provides a universal probe, in which, from 5′ end to 3′ end, the universal probe sequentially comprises: quenching group-fragment A -fluorophore-fragment B-C3; the fragment A has a nucleotide sequence selected from a group consisting of SEQ ID NO:1-7; and the fragment B has a nucleotide sequence selected from a group consisting of SEQ ID NO:8-14. The present application further provide a primer-probe set, an application and the kit.

Description

REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

The contents of the electronic sequence listing (SequenceListing.xml; Size: 91,085 bytes; and Date of Creation: May 31, 2023) is herein incorporated by reference.

TECHNICAL FIELD

The present application relates to a field of a biological detection technology, in particular, relates to a universal probe, a primer-probe set and a kit.

BACKGROUND ART

A pathogenic microorganism is a microorganism that can cause an infectious disease or even a communicable disease after invading a human body. Common pathogenic microorganisms include prion, bacterium, mycoplasma, chlamydia, rickettsia, fungi, spirochete and virus. After repetitive exposure to some chemotherapeutic drugs, a reactivity of these pathogenic microorganisms continues to decrease, so that finally the pathogenic microorganisms can resist the drug without being killed or inhibited, and thus develop a tolerance to drugs, that is, a drug tolerance or drug resistance. A resistant gene is a nucleotide sequence encoding a drug resistance property, and is located on a chromosome of the bacterium or a plasmid outside the chromosomal. If the pathogenic microorganisms develop the drug resistance, an efficacy is commonly reduced or completely lost, which directly affect a therapeutic effect against the disease. Thus, establishing a systematic, efficient, and fast detection method for identifying a nucleic acid of a plurality of pathogenic microorganisms and resistant genes can effectively promote the development of the medical industry.

At present, a conventional detection method of nucleic acids of the pathogenic microorganisms and resistant genes mainly adopts a real-time quantitative PCR (qPCR), including a fluorescent dye method (SYBR Green I method is a representative) and a fluorescent probe method (TaqMan method is the representative). The SYBR Green I method is widely used due to advantages such as convenient use and low price, but a biggest disadvantage thereof is a lack of a specificity, that is, a dye can be combined with any dsDNA, which affects an accuracy of a quantitative result. Different from the fluorescent dye method, the TaqMan method detection involves an addition of a fluorescent probe, which works through fluorescence resonance energy transfer (FRET), and has a high specificity and suitability for multiplex qPCR. However, a traditional TaqMan probe technology usually requires one probe for each of the targets. However, when detecting multiple targets in one fluorescence channel, if there are too many probes labeled with a same fluorescence, it will lead to a high background signal and decreased contrast, resulting in difficult signal interpretation difficult and limited number of targets that can be detected.

SUMMARY

In view of this, a technical problem to be solved by the present application is to provide a primer-probe set and a kit containing the primer-probe for a digital PCR detection of a plurality of pathogenic microorganisms and resistant genes. The present application provides a digital PCR platform based on a 7-color fluorescence channel and in combination with multiplex digital PCR technology to achieve a coverage of multiple bacterial strains or drug resistance sites for each species.

The present application provides a universal probe structure, from 5′ end to 3′ end, the universal probe sequentially including: quenching group-fragment A-fluorophore-fragment B-C3.

In some embodiments, the fragment A has a nucleotide sequence selected from a group consisting of SEQ ID NO:1-7.

the fragment B has a nucleotide sequence selected from a group consisting of SEQ ID NO:8-14.

In some embodiments, from 5′ end to 3′ end, the universal probe sequentially includes one selected from a group consisting of:

• • quenching group-fragment A having a nucleotide sequence of SEQ ID NO:1-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:8;
  • quenching group-fragment A having a nucleotide sequence of SEQ ID NO:2-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:9;
  • quenching group-fragment A having a nucleotide sequence of SEQ ID NO:3-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:10;
  • quenching group-fragment A having a nucleotide sequence of SEQ ID NO:4-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:11;
  • quenching group-fragment A having a nucleotide sequence of SEQ ID NO:5-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:12;
  • quenching group-fragment A having a nucleotide sequence of SEQ ID NO:6-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:13; and
  • quenching group-fragment A having a nucleotide sequence of SEQ ID NO:7-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:14.

The fluorophore of the universal probe described in the present application is selected from a group consisting of FAM, VIC, ROX, CY5, A425, CY5.5 and CY7; and the quenching group is selected from a group consisting of BHQ1, BHQ2 and BHQ3.

In some embodiments, the fluorophore A425 of the universal probe is fluorophore ATT0425.

In some embodiments, from 5′ end to 3′ end, the universal probe sequentially includes one selected from a group consisting of:

• • BHQ1-fragment A having a nucleotide sequence of SEQ ID NO:1-dT-FAM-fragment B-C3 having a nucleotide sequence of SEQ ID NO:8;
  • BHQ1-fragment A having a nucleotide sequence of SEQ ID NO:2-dT-VIC-fragment B-C3 having a nucleotide sequence of SEQ ID NO:9;
  • BHQ2-fragment A having a nucleotide sequence of SEQ ID NO:3-dT-ROX-fragment B-C3 having a nucleotide sequence of SEQ ID NO:10;
  • BHQ2-fragment A having a nucleotide sequence of SEQ ID NO:4-dT-CY5-fragment B-C3 having a nucleotide sequence of SEQ ID NO:11;
  • BHQ1-fragment A having a nucleotide sequence of SEQ ID NO:5-dT-A425-fragment B-C3 having a nucleotide sequence of SEQ ID NO:12;
  • BHQ3-fragment A having a nucleotide sequence of SEQ ID NO:6-dT-CY5.5 -fragment B-C3 having a nucleotide sequence of SEQ ID NO:13; and
  • BHQ3-fragment A having a nucleotide sequence of SEQ ID NO:7-dT-CY7-fragment B-C3 having a nucleotide sequence of SEQ ID NO:14.

In the present application, the universal probe is in cooperation with a single-modified fluorescence-free probe. In particular, the single-modified fluorescence-free probe is specifically combined with an amplification product, and the universal probe is hybridized with a hydrolyzed fragment of the single-modified fluorescence-free probe to generate a fluorescent signal for a detection purpose.

The present application further provides a primer-probe set for detecting one selected from a group consisting of the pathogenic microorganism and the resistant gene, including the universal probe described in the present application.

The primer-probe set provided in the present application further includes a specific primer pair targeting the pathogenic microorganism and the resistant gene.

In particular, the pathogenic microorganism includes one selected from a group consisting of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Enterobacter cloacae, Candida albicans, Candida glabrata, Candida parapsilosis and Candida tropicalis;

• • the resistant gene includes one selected from a group consisting of carbapenem resistant KPC gene, carbapenem resistant NDM gene, carbapenem resistant OXA48 gene, carbapenem resistant IMP gene, vancomycin resistant vanA gene, vancomycin resistant vanB gene, vancomycin resistant vanM gene, methicillin resistant mecA gene and methicillin resistant mecC gene.

Specifically, a primer pair targeting the Pseudomonas aeruginosa has a nucleotide sequence selected from a group consisting of SEQ ID NO:37-38;

• • a primer pair targeting the Escherichia coli has a nucleotide sequence selected from a group consisting of SEQ ID NO:39-40;
  • a primer pair targeting the Klebsiella pneumoniae has a nucleotide sequence selected from a group consisting of SEQ ID NO:41-42;
  • a primer pair targeting the Acinetobacter baumannii has a nucleotide sequence selected from a group consisting of SEQ ID NO:43-44;
  • a primer pair targeting the Staphylococcus aureus has a nucleotide sequence selected from a group consisting of SEQ ID NO:45-46;
  • a primer pair targeting the Enterococcus faecium has a nucleotide sequence selected from a group consisting of SEQ ID NO:47-48;
  • a primer pair targeting the Enterococcus faecalis has a nucleotide sequence selected from a group consisting of SEQ ID NO:49-50;
  • a primer pair targeting the Enterobacter cloacae has a nucleotide sequence selected from a group consisting of SEQ ID NO:51-52;
  • a primer pair targeting the Candida albicans has a nucleotide sequence selected from a group consisting of SEQ ID NO:53-54;
  • a primer pair targeting the Candida glabrata has a nucleotide sequence selected from a group consisting of SEQ ID NO:55-56;
  • a primer pair targeting the Candida parapsilosis has a nucleotide sequence selected from a group consisting of SEQ ID NO:57-58;
  • a primer pair targeting the Candida tropicalis has a nucleotide sequence selected from a group consisting of SEQ ID NO:59-60;
  • a primer pair targeting the carbapenem resistant KPC gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:61-62;
  • a primer pair targeting the carbapenem resistant NDM gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:63-64;
  • a primer pair targeting the carbapenem resistant OXA48 gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:65-66;
  • a primer pair targeting the carbapenem resistant IMP gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:67-68;
  • a primer pair targeting the vancomycin resistant vanA gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:69-70;
  • a primer pair targeting the vancomycin resistant vanB gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:71-72;
  • a primer pair targeting the vancomycin resistant vanM gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:73-74;
  • a primer pair targeting the methicillin resistant mecA gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:75-76; and,
  • a primer pair targeting the methicillin resistant mecC gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:77-78.

The primer-probe set provided in the present application further includes the single-modified fluorescence-free probe, a nucleotide sequence of the single-modified fluorescence-free probe is reversely complementary to a nucleotide sequence of the fragment B in the universal probe, and 3′ end of the single-modified fluorescence-free probe is labeled with the quenching group. In particular, the quenching group is selected from a group consisting of MGB, BHQ1, BHQ2 and BHQ3.

Specifically, a single-modified fluorescence-free probe targeting the Pseudomonas aeruginosa has a nucleotide sequence as shown in SEQ ID NO:15, and 3′ end is labeled with the MGB quenching group;

• • a single-modified fluorescence-free probe targeting the Escherichia coli has a nucleotide sequence as shown in SEQ ID NO:16, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Klebsiella pneumoniae has a nucleotide sequence as shown in SEQ ID NO:17, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Acinetobacter baumannii has a nucleotide sequence as shown in SEQ ID NO:18, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Staphylococcus aureus has a nucleotide sequence as shown in SEQ ID NO:19, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Enterococcus faecium has a nucleotide sequence as shown in SEQ ID NO:20, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Enterococcus faecalis has a nucleotide sequence as shown in SEQ ID NO:21, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Enterobacter cloacae has a nucleotide sequence as shown in SEQ ID NO:22, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Candida albicans has a nucleotide sequence as shown in SEQ ID NO:23, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Candida glabrata has a nucleotide sequence as shown in SEQ ID NO:24, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Candida parapsilosis has a nucleotide sequence as shown in SEQ ID NO:25, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the Candida tropicalis has a nucleotide sequence as shown in SEQ ID NO:26, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the carbapenem resistant KPC gene has a nucleotide sequence as shown in SEQ ID NO:27, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the carbapenem resistant NDM gene has a nucleotide sequence as shown in SEQ ID NO:28, and 3′ end is labeled with the BHQ2 quenching group;
  • a single-modified fluorescence-free probe targeting the carbapenem resistant OXA48 gene has a nucleotide sequence as shown in SEQ ID NO:29, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the carbapenem resistant IMP gene has a nucleotide sequence as shown in SEQ ID NO:30, and 3′ end is labeled with the MGB quenching group;
  • a single-modified fluorescence-free probe targeting the vancomycin resistant vanA gene has a nucleotide sequence as shown in SEQ ID NO:31, and 3′ end is labeled with the BHQ1 quenching group;
  • a single-modified fluorescence-free probe targeting the vancomycin resistant vanB gene has a nucleotide sequence as shown in SEQ ID NO:32, and 3′ end is labeled with the BHQ1 quenching group;
  • a single-modified fluorescence-free probe targeting the vancomycin resistant vanM gene has a nucleotide sequence as shown in SEQ ID NO:33, and 3′ end is labeled with the BHQ1 quenching group;
  • a single-modified fluorescence-free probe targeting the methicillin resistant mecA gene has a nucleotide sequence as shown in SEQ ID NO:34, and 3′ end is labeled with the BHQ2 quenching group;
  • a single-modified fluorescence-free probe targeting the methicillin resistant mecC gene has a nucleotide sequence as shown in SEQ ID NO:35, and 3′ end is labeled with the MGB quenching group.

The present application further provides an application of the universal probe or the primer-probe set in a preparation of digital PCR detection reagents for a plurality of pathogenic microorganisms and resistant genes.

The present application further provides a kit for detecting one selected from a group consisting of a plurality of pathogenic microorganisms and resistant genes, including one selected from a group consisting of the universal probe or the primer-probe set described in the present application.

The kit provided in the present application further includes a combination of a primer and a probe for an internal control gene, having the following sequences: IC-UP7: ctgcacgaagctctttttcccgcgacggatctacgtcacagcg (SEQ ID NO:36); IC-P: cgcgacggatctacgtcacagcg (SEQ ID NO:102); IC-F: gcttcttgtggagctcgacaa (SEQ ID NO:79); IC-R: ccgtcagcaacttcgttttca (SEQ ID NO:80).

The present application further provides a multiplex digital PCR detection method for a plurality of pathogenic microorganisms and resistant genes, utilizing the primer-probe set or the kit of the present application for detection.

The detection method based on a multiplex digital PCR platform includes the following steps:

• • (1) a nucleic acid of a sample to be tested is extracted;
  • (2) multiplex digital PCR amplification system is configured;
  • (3) an amplification program is run: 95 ° C. 5 min, (95 ° C. 15 s, 60 ° C. 1 min) x 40;
  • (4) a result is output.

By using the primer-probe of the present application, a joint detection of 12 pathogenic microorganisms and 9 resistant genes can be achieved. In particular, the pathogenic microorganisms includes one selected from a group consisting of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Enterobacter cloacae, Candida albicans, Candida glabrata, Candida parapsilosis and Candida tropicalis; and the resistant genes include one selected from a group consisting of carbapenem resistant KPC gene, carbapenem resistant NDM gene, carbapenem resistant OXA48 gene, carbapenem resistant IMP gene, vancomycin resistant vanA gene, vancomycin resistant vanB gene, vancomycin resistant vanM gene, methicillin resistant mecA gene and methicillin resistant mecC gene.

For conservative regions of 12 pathogenic microorganisms and 9 resistant genes, the present application specifically designs 42 primers, 7 universal probes containing different fluorophores and 21 specific single-modified fluorescence-free probes in total. The universal probe is cooperated with a single-modified probe to generate the fluorescent signal, which can be used to detect whether the sample contains Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Enterobacter cloacae, Candida albicans, Candida glabrata, Candida parapsilosis or Candida tropicalis in the sample, and detect whether the sample contains a site of carbapenem resistant KPC gene, carbapenem resistant NDM gene, carbapenem resistant OXA48 gene, carbapenem resistant IMP gene, vancomycin resistant vanA gene, vancomycin resistant vanB gene, vancomycin resistant vanM gene, methicillin resistant mecA gene or methicillin resistant mecC gene.

The present application adopts a single amplification system with a conventional double-modified probe and a multiplex amplification system with a cooperation of the universal probe and the single-modified probe, and the detection results of the two systems are consistent with each other, which ensures a feasibility of designing the universal probe containing different fluorophores for a target gene and combining them with the specific single-modified fluorescence-free probe to conduct the multiplex digital PCR.

DETAILED DESCRIPTION

The present application provides a primer-probe set and a kit thereof for a digital PCR detection of a plurality of pathogenic microorganisms and resistant genes, and those skilled in the art can appropriately improve a process parameter by learning from a content of the present application. It should be noted that, all similar replacements and modifications are apparent to those skilled in the art and are considered to fall within a scope of the present invention. A method and an application of the present application have been described through a preferred embodiment, and it is obvious that a relevant personnel can make modifications or appropriate changes and combinations of the method and application without departing from the content, spirit and scope of the present application to achieve and apply a technology of the present application.

Test materials used in the present application are all common commercially available and can be purchased in the market.

The present application is further described below in combination with examples.

EXAMPLE 1

Design of the Primer-Probe Set of the Present Application

A sequence of the primer-probe set involved in this example is shown in Table 1.

In particular, UP1-UP7 represents 7 universal probes with different colors. F represents an upstream primer, R represents a downstream primer, and P represents the probe. For example, TL-F represents an upstream primer of the Pseudomonas aeruginosa, TL-R represents a downstream primer of the Pseudomonas aeruginosa, TL-P represents a conventional double-modified probe of the Pseudomonas aeruginosa, and TL-UP1 represents the specific single-modified fluorescence-free probe of the Pseudomonas aeruginosa.

TABLE 1
			5′	3′
			modi-	modi-
Name	Number	Sequence	fication	fication
universal probe	fragment A	Agccccctcagggtccagggggc (SEQ ID NO: 1)	BHQ1
universal probe	fragment A	aggccccctgctacgtgggggcc (SEQ ID NO: 2)	BHQ1
universal probe	fragment A	agggcccctgactgccagggccc (SEQ ID NO: 3)	BHQ2
universal probe	fragment A	aggggccctggcatgctggcccc (SEQ ID NO: 4)	BHQ2
universal probe	fragment A	agggggccaaggtccgagccccc (SEQ ID NO: 5)	BHQ1
universal probe	fragment A	aggggggcgacgtcggtcccccc (SEQ ID NO: 6)	BHQ3
universal probe	fragment A	agccgggcgacgtcggtcccggc (SEQ ID NO: 7)	BHQ3
universal probe	fragment B	catgctgaggtgtagacccatggattcc (SEQ ID NO: 8)		C3
universal probe	fragment B	catgctgttaccaggccccctctcc (SEQ ID NO: 9)		C3
universal probe	fragment B	catgctcatcccaaaatatgggctaacacc (SEQ ID		C3
		NO: 10)
universal probe	fragment B	catgctcgatctcgaatcgaagcacc (SEQ ID NO: 11)		C3
universal probe	fragment B	catggaaatgggtagacaaagcaggcc (SEQ ID		C3
		NO: 12)
universal probe	fragment B	catgctgtctgcaacacgaagctcc (SEQ ID NO: 13)		C3
universal probe	fragment B	catgggaaaaagagcttcgtgcagc (SEQ ID NO: 14)		C3
pseudomonas	TL-UP1	gaatccatgggtctacacctcagccttgacatgctgagaac		MGB
aeruginosa		(SEQ ID NO: 15)
escherichia	DC-UP1	gaatccatgggtctacacctcagcaagggagtaaagttaatac		MGB
coli		c (SEQ ID NO: 16)
klebsiella	FK-UP1	gaatccatgggtctacacctcagcataacctcatcgattgacg		MGB
pneumoniae		(SEQ ID NO: 17)
acinetobacter	BM-UP1	gaatccatgggtctacacctcagcttgacatactagaaactt		MGB
baumannii		(SEQ ID NO: 18)
staphylococcus	JP-UP2	gagagggggcctggtaacagcatagagccttccccttcg		MGB
aureus		(SEQ ID NO: 19)
enterococcus	SC-UP2	gagagggggcctggtaacagcatagagcttccccttcgg		MGB
faecium		(SEQ ID NO: 20)
enterococcus	FC-UP2	gagagggggcctggtaacagcagagctttcccttcgg		MGB
faecalis		(SEQ ID NO: 21)
enterobacter	YG-UP2	gagagggggcctggtaacagcaaggtgttgtggttaataa		MGB
cloacae		(SEQ ID NO: 22)
candida	BS-UP3	gtgttagcccatattttgggatgagcctgttatcccaayaca		MGB
albicans		aac (SEQ ID NO: 23)
candida	GH-UP3	gtgttagcccatattttgggatgagcactaccagcagatgcg		MGB
glabrata		(SEQ ID NO: 24)
candida	JPH-UP3	gtgttagcccatattttgggatgagcattagtatcggaagaact		MGB
parapsilosis		ca (SEQ ID NO: 25)
candida	RD-UP3	gtgttagcccatattttgggatgagcagtatgtattctttaac		MGB
parapsilosis		acgttg (SEQ ID NO: 26)
carbapenem	KPC-UP4	gtgcttcgattcgagatcgagccgctgcggctagac (SEQ		MGB
resistant KPC		ID NO: 27)
carbapenem	NDM-UP4	gtgcttcgattcgagatcgagccggtcgcgctggc (SEQ		BHQ2
resistant NDM		ID NO: 28)
carbapenem	OXA48-UP4	gtgcttcgattcgagatcgagatttgggcgtggttaagga		MGB
resistant		(SEQ ID NO: 29)
OXA48
carbapenem	IMP-UP4	gtgcttcgattcgagatcaagagtgatgcgtctc (SEQ ID		MGB
resistant IMP		NO: 30)
vancomycin	vanA-UP5	gcctgctttgtctacccatttccagcagaggagcgagg		BHQ1
resistant vanA		(SEQ ID NO: 31)
vancomycin	VANB-UP5	gcctgctttgtctacccagagaatacgaaactcg (SEQ ID		BHQ1
resistant vanB		NO: 32)
vancomycin	VANM-UP5	gcctgctttgtctacccatttgaaccaatatacatcggaata		BHQ1
resistant vanM		(SEQ ID NO: 33)
methicillin	MECA-UP6	gagcttcgtgttgcagacagcatgttaaagaagatggtatgtg		BHQ2
resistant mecA		g (SEQ ID NO: 34)
methicillin	mecC-UP6	gagcttcgtgttgcagacagccttttataaagcacaaatc		MGB
resistant mecC		(SEQ ID NO: 35)
exogenous	IC-UP7	ctgcacgaagctctttttcccgcgacggatctacgtcacagcg		BHQ3
internal control		(SEQ ID NO: 36)
pseudomonas	TL-F	gcaacgegaagaaccttacc (SEQ ID NO: 37)
aeruginosa
pseudomonas	TL-R	gttcccgaaggcaccaatc (SEQ ID NO: 38)
aeruginosa
escherichia	DC-F	ggccttcgggttgtaaagtac (SEQ ID NO: 39)
coli
escherichia	DC-R	tcttctgcgggtaacgtcaat (SEQ ID NO: 40)
coli
klebsiella	FK-F	agcctgatgcagccatgc (SEQ ID NO: 41)
pneumoniae
klebsiella	FK-R	ttagccggtgcttcttctgc (SEQ ID NO: 42)
pneumoniae
acinetobacter	BM-F	gcaacgcgaagaaccttacc (SEQ ID NO: 43)
baumannii
acinetobacter	BM-R	gttcccgaaggcaccaatc (SEQ ID NO: 44)
baumannii
staphylococcus	JP-F	gcaacgcgaagaaccttacc (SEQ ID NO: 45)
aureus
staphylococcus	JP-R	catgcaccacctgtcactttg (SEQ ID NO: 46)
aureus
enterococcus	SC-F	gcaacgegaagaaccttacc (SEQ ID NO: 47)
faecium
enterococcus	SC-R	catgcaccacctgtcactttg (SEQ ID NO: 48)
faecium
enterococcus	FC-F	ggtggagcatgtggtttaattcga (SEQ ID NO: 49)
faecalis
enterococcus	FC-R	ctcacgacacgagctgacgac (SEQ ID NO: 50)
faecalis
enterobacter	YG-F	tcctacgggaggcagcagt (SEQ ID NO: 51)
cloacae
enterobacter	YG-R	ctgctggcacggagttagc (SEQ ID NO: 52)
cloacae
candida	BS-F	tgcccaacagcaactrsaagt (SEQ ID NO: 53)
albicans
candida	BS-R	gaagccatttgttgtgatgtttg (SEQ ID NO: 54)
albicans
candida	GH-F	gagtttcttcgacaacgggtactac (SEQ ID NO: 55)
glabrata
candida	GH-R	tcctccggcaccacatg (SEQ ID NO: 56)
glabrata
candida	JPH-F	tgtggcgtcattgtgtaacaaa (SEQ ID NO: 57)
parapsilosis
candida	JPH-R	attgtgttgtttcaccgatgttg (SEQ ID NO: 58)
parapsilosis
candida	RD-F	catccattggttgatttttcca (SEQ ID NO: 59)
tropicalis
candida	RD-R	tggatcgacaaaaagaaaaagga (SEQ ID NO: 60)
tropicalis
carbapenem	KPC-F	ggcgcctaacaaggatgaca (SEQ ID NO: 61)
resistant KPC
carbapenem	KPC-R	gacgcccaatccctcgag (SEQ ID NO: 62)
resistant KPC
carbapenem	NDM-F	ctggatcaagcaggagatcaac (SEQ ID NO: 63)
resistant NDM
carbapenem	NDM-R	cgcccatcttgtcctgatg (SEQ ID NO: 64)
resistant NDM
carbapenem	OXA48-F	cccaatagcttcatcgccct (SEQ ID NO: 65)
resistant
OXA48
carbapenem	OXA48-R	gtccatcccacttaaagacttggt (SEQ ID NO: 66)
resistant
OXA48
carbapenem	IMP-F	gcaaaactggttgttccargtca (SEQ ID NO: 67)
resistant IMP
carbapenem	IMP-R	aaycctttaaccgcctgctcta (SEQ ID NO: 68)
resistant IMP
vancomycin	vanA-F	ccgttcccgcagacctt (SEQ ID NO: 69)
resistant vanA
vancomycin	vanA-R	ttttttgccgtttcctgtatcc (SEQ ID NO: 70)
resistant vanA
vancomycin	vanB-F	catggtctgcttgtcatgaaaga (SEQ ID NO: 71)
resistant vanB
vancomycin	vanB-R	gggaaagccacgtcaatacg (SEQ ID NO: 72)
resistant vanB
vancomycin	vanM-F	gcagagattgccaacaacattga (SEQ ID NO: 73)
resistant vanM
vancomycin	vanM-R	gcatgttttccaaacgcca (SEQ ID NO: 74)
resistant vanM
methicillin	mecA-F	aactacggtaacattgatcgcaac (SEQ ID NO: 75)
resistant mecA
methicillin	mecA-R	gcattcctggaataatgacgcta (SEQ ID NO: 76)
resistant mecA
methicillin	mecC-F	cggtgaaaatatcccgagtga
resistant mecC		(SEQ ID NO: 77)
methicillin	mecC-R	ggccatatcctgaatctgctaataa
resistant mecC		(SEQ ID NO: 78)
exogenous	IC-F	gcttcttgtggagctcgacaa (SEQ ID NO: 79)
internal control
exogenous	IC-R	ccgtcagcaacttcgttttca (SEQ ID NO: 80)
internal control
pseudomonas	TL-P	ccttgacatgctgagaac (SEQ ID NO: 81)	FAM	MGB
aeruginosa
escherichia	DC-P	aagggagtaaagttaatacc (SEQ ID NO: 82)	FAM	MGB
coli
klebsiella	FK-P	taacctcatcgattgacg (SEQ ID NO: 83)	FAM	MGB
pneumoniae
acinetobacter	BM-P	ccttgacatactagaaactt (SEQ ID NO: 84)	FAM	MGB
baumannii
staphylococcus	JP-P	tagagccttccccttcg (SEQ ID NO: 85)	VIC	MGB
aureus
enterococcus	SC-P	atagagcttccccttcgg (SEQ ID NO: 86)	VIC	MGB
faecium
enterococcus	FC-P	agagctttcccttcgg (SEQ ID NO: 87)	VIC	MGB
faecalis
enterobacter	YG-P	aaggtgttgtggttaataa (SEQ ID NO: 88)	VIC	MGB
cloacae
candida	BS-P	cctgttatcccaayacaaac (SEQ ID NO: 89)	ROX	MGB
albicans
candida	GH-P	actaccagcagatgcg (SEQ ID NO: 90)	ROX	MGB
glabrata
candida	JPH-P	ttagtatoggaagaactca (SEQ ID NO: 91)	ROX	MGB
parapsilosis
candida	RD-P	cagtatgtattctttaacacgttg (SEQ ID NO: 92)	ROX	MGB
tropicalis
carbapenem	KPC-P	gccgctgeggctagac (SEQ ID NO: 93)	CY5	MGB
resistant KPC
carbapenem	NDM-P	gccggtcgcgctggc (SEQ ID NO: 94)	CY5	BHQ2
resistant NDM
carbapenem	OXA48-P	gatttgggcgtggttaagga (SEQ ID NO: 95)	CY5	MGB
resistant
OXA48
carbapenem	IMP-P	caagagtgatgcgtctc (SEQ ID NO: 96)	CY5	MGB
resistant IMP
vancomycin	vanA-P	cagcagaggagcgagg (SEQ ID NO: 97)	A425	BHQ1
resistant vanA
vancomycin	vanB-P	agagaatacgaaactcg (SEQ ID NO: 98)	A425	BHQ1
resistant vanB
vancomycin	vanM-P	tgaaccaatatacatcggaata (SEQ ID NO: 99)	A425	BHQ1
resistant vanM
methicillin	mecA-P	tgttaaagaagatggtatgtgg (SEQ ID NO: 100)	CY5.5	BHQ2
resistant mecA
methicillin	mecC-P	ccttttataaagcacaaatc (SEQ ID NO: 101)	CY5.5	MGB
resistant mecC
exogenous	IC-P	cgcgacggatctacgtcacagcg (SEQ ID NO: 102)	CY7	BHQ3
internal control

EXAMPLE 2

Digital PCR Amplification System

1. A single amplification system is shown in Table 2

TABLE 2
	Concentration of
Component	storage solution (μM)	Volume (μL)
water		9.475
5 × Taq mix		3
50 × positioning dye		0.3
F	400	0.0375
R	400	0.0375
P	100	0.0375
IC-F	400	0.0375
IC-R	400	0.0375
IC-P	100	0.0375
IC template		1
Bacterium DNA/resistant gene		1
total		15

2. A multiplex amplification system is shown in Table 3

TABLE 3
	Concentration of	Volume
Component	storage solution (μM)	(μL/test)
water		6.4375
5 × Taq mix		3
UP1	100	0.0375
UP2	100	0.0375
UP3	100	0.0375
UP4	100	0.0375
UP5	100	0.0375
UP6	100	0.0375
UP7	100	0.0375
TL-F	400	0.0375
TL-R	400	0.0375
TL-UP1	100	0.0375
DC-F	400	0.0375
DC-R	400	0.0375
DC-UP1	100	0.0375
FK-F	400	0.0375
FK-R	400	0.0375
FK-UP1	100	0.0375
BM-F	400	0.0375
BM-R	400	0.0375
BM-UP1	100	0.0375
JP = F	400	0.0375
JP-R	400	0.0375
JP-UP2	100	0.0375
SC-F	400	0.0375
SC-R	400	0.0375
SC-UP2	100	0.0375
FC-F	400	0.0375
FC-R	400	0.0375
FC-UP2	100	0.0375
YG-F	400	0.0375
YG-R	400	0.0375
YG-UP2	100	0.0375
BS-F	400	0.0375
BS-R	400	0.0375
BS-UP3	100	0.0375
GH-F	400	0.0375
GH-R	400	0.0375
GH-UP3	100	0.0375
JPH-F	400	0.0375
JPH-R	400	0.0375
JPH-UP3	100	0.0375
RD-F	400	0.0375
RD-R	400	0.0375
RD-UP3	100	0.0375
KPC-F	400	0.0375
KPC-R	400	0.0375
KPC-UP4	100	0.0375
NDM-F	400	0.0375
NDM-R	400	0.0375
NDM-UP4	100	0.0375
OXA48-F	400	0.0375
OXA48-R	400	0.0375
OXA48-UP4	100	0.0375
IMP-F	400	0.0375
IMP-R	400	0.0375
IMP-UP4	100	0.0375
vanA-F	400	0.0375
vanA-R	400	0.0375
vanA-UP5	100	0.0375
vanB-F	400	0.0375
vanB-R	400	0.0375
vanB-UP5	100	0.0375
vanM-F	400	0.0375
vanM-R	400	0.0375
vanM-UP5	100	0.0375
mecA-F	400	0.0375
mecA-R	400	0.0375
mecA-UP6	100	0.0375
mecC-F	400	0.0375
mecC-R	400	0.0375
mecC-UP6	100	0.0375
IC-F	400	0.0375
IC-R	400	0.0375
IC-UP7	100	0.0375
IC template		1
Bacterium DNA/resistant gene		1
total		15

3. An Amplification Program

95° C. 5 min, (95° C. 15 s, 60° C. 1 min)×40

4. A Result Interpretation

(1) A detection result of the single amplification system is shown in Table 4

TABLE 4
	A425	FAM	VIC	ROX	CY5	CY5.5	CY7
Sample	(copies/μL)	(copies/μL)	(copies/μL)	(copies/μL)	(copies/μL)	(copies/μL)	(copies/μL)
pseudomonas	/	108.44	/	/	/	/	258.64
aeruginosa
escherichia coli	/	218.62	/	/	/	/	267.33
klebsiella	/	58.17	/	/	/	/	249.66
pneumoniae
acinetobacter	/	333.19	/	/	/	/	263.55
baumannii
staphylococcus	/	/	1186.95	/	/	/	248.71
aureus
enterococcus	/	/	2137.44	/	/	/	265.89
faecium
enterococcus	/	/	29.66	/	/	/	252.12
faecalis
enterobacter	/	/	87.11	/	/	/	267.81
cloacae
candida albicans	/	/	/	45.19	/	/	257.75
candida glabrata	/	/	/	86.77	/	/	249.46
candida	/	/	/	83.98	/	/	252.33
parapsilosis
candida tropicalis	/	/	/	36.44	/	/	249.6
carbapenem	/	/	/	/	109.53	/	246.28
resistant KPC
carbapenem	/	/	/	/	218.62	/	258.47
resistant NDM
carbapenem	/	/	/	/	317.4	/	245.54
resistant OXA48
carbapenem	/	/	/	/	211.09	/	247.9
resistant IMP
vancomycin	319.9	/	/	/	/	/	251.11
resistant vanA
vancomycin	856.71	/	/	/	/	/	259.14
resistant vanB
vancomycin	2365.47	/	/	/	/	/	246.77
resistant vanM
methicillin	/	/	/	/	/	1166.22	248.83
resistant mecA
methicillin	/	/	/	/	/	2312.89	264
resistant mecC

(2) A detection result of the multiplex amplification system is shown in Table 5

TABLE 5
	A425	FAM	VIC	ROX	CY5	CY5.5	CY7
Sample	(copies/μL)	(copies/μL)	(copies/μL)	(copies/μL)	(copies/μL)	(copies/μL)	(copies/μL)
pseudomonas	0	124.16	0	0	0	0	248.66
aeruginosa
escherichia coli	0	214.33	0	0	0	0	243.77
klebsiella	0	55.22	0	0	0	0	265.56
pneumoniae
acinetobacter	0	324.5	0	0	0	0	249.35
baumannii
staphylococcus	0	0	1150.33	0	0	0	243.22
aureus
enterococcus	0	0	2140.62	0	0	0	249.17
faecium
enterococcus	0	0	35.16	0	0	0	256.71
faecalis
enterobacter	0	0	85.29	0	0	0	256.33
cloacae
candida albicans	0	0	0	48.27	0	0	265.81
candida glabrata	0	0	0	85.66	0	0	268.66
candida	0	0	0	89.42	0	0	259.18
parapsilosis
candida tropicalis	0	0	0	32.15	0	0	246.83
carbapenem	0	0	0	0	106.24	0	247.5
resistant KPC
carbapenem	0	0	0	0	215.43	0	258.6
resistant NDM
carbapenem	0	0	0	0	321.99	0	240.21
resistant OXA48
carbapenem	0	0	0	0	205.32	0	253.17
resistant IMP
vancomycin	314.44	0	0	0	0	0	248.59
resistant vanA
vancomycin	850.41	0	0	0	0	0	252.33
resistant vanB
vancomycin	2377.82	0	0	0	0	0	242.59
resistant vanM
methicillin	0	0	0	0	0	1145.54	262.13
resistant mecA
methicillin	0	0	0	0	0	2320.17	247.7
resistant mecC

The results showed that the Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii only had detection values in FAM and CY7, and there was no detection value in other channels.

The Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis and Enterobacter cloacae only had detection values in VIC and CY7, and there was no detection value in other channels.

The Candida albicans, Candida glabrata, Candida parapsilosis and Candida tropicalis only had detection values in ROX and CY7, and there was no detection value in other channels.

The carbapenem resistant genes only had detection values in CY5 and CY7, and there was no detection value in other channels.

The vancomycin resistant genes only had detection values in A425 and CY7, and there was no detection value in other channels.

The methicillin resistant genes only had detection values in CY5.5 and CY7, and there was no detection value in other channels.

In summary, the primers and probes provided by the present application can accurately detect a simulated sample, and the detection results were fully consistent with an expectation, which indicated that an accuracy of the detection system was normal. The system for detecting a plurality of pathogenic microorganisms and resistant genes in the present application had specificity. The detection results of the two detection systems were basically consistent, which indicated that the multiplex detection system of the present application has stability.

The above are the preferred embodiments of the present application. It should be noted that, those skilled in the art can make several changes or modifications according without departing from the principles of the present application, which should be covered within the protection scope of the present application.

Claims

1. A universal probe, wherein, from 5′ end to 3′ end, the universal probe sequentially comprises: quenching group-fragment A-fluorophore-fragment B-C3; the fragment A has a nucleotide sequence selected from a group consisting of SEQ ID NO:1-7; andthe fragment B has a nucleotide sequence selected from a group consisting of SEQ ID NO:8-14.

2. The universal probe according to claim 1, wherein, from 5′ end to 3′ end, the universal probe sequentially comprises one selected from a group consisting of: quenching group-fragment A having a nucleotide sequence of SEQ ID NO:1-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:8;quenching group-fragment A having a nucleotide sequence of SEQ ID NO:2-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:9;quenching group-fragment A having a nucleotide sequence of SEQ ID NO:3-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:10;quenching group-fragment A having a nucleotide sequence of SEQ ID NO:4-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:11;quenching group-fragment A having a nucleotide sequence of SEQ ID NO:5-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:12;quenching group-fragment A having a nucleotide sequence of SEQ ID NO:6-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:13; andquenching group-fragment A having a nucleotide sequence of SEQ ID NO:7-fluorophore-fragment B-C3 having a nucleotide sequence of SEQ ID NO:14.

3. The universal probe according to claim 1, wherein, the fluorophore is selected from a group consisting of FAM, VIC, ROX, CY5, A425, CY5.5 and CY7; and the quenching group is selected from a group consisting of BHQ1, BHQ2 and BHQ3.

4. A primer-probe set for detecting one selected from a group consisting of a pathogenic microorganism and a resistant gene, comprising the universal probe according to claim 1, a specific primer pair and a single-modified fluorescence-free probe, wherein the specific primer pair targets the pathogenic microorganism and the resistant gene.

5. The primer-probe set according to claim 4, wherein, a nucleotide sequence of the single-modified fluorescence-free probe is reversely complementary to the nucleotide sequence of the fragment B in the universal probe.

6. The primer-probe set according to claim 5, wherein, 3′ end of the single-modified fluorescence-free probe is labeled with the quenching group.

7. The primer-probe set according to claim 6, wherein, the quenching group labeled at 3′ end of the single-modified fluorescence-free probe is selected from MGB, BHQ1, BHQ2 and BHQ3.

8. The primer-probe set according to claim 4, wherein, the single-modified fluorescence-free probe has a nucleotide sequence selected from a group consisting of SEQ ID NO:15-36.

9. The primer-probe set according to claim 4, wherein, the pathogenic microorganism comprises one selected from a group consisting of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Enterobacter cloacae, Candida albicans, Candida glabrata, Candida parapsilosis and Candida tropicalis; and the resistant gene comprises one selected from a group consisting of carbapenem resistant KPC gene, carbapenem resistant NDM gene, carbapenem resistant OXA48 gene, carbapenem resistant IMP gene, vancomycin resistant vanA gene, vancomycin resistant vanB gene, vancomycin resistant vanM gene, methicillin resistant mecA gene and methicillin resistant mecC gene.

10. The primer-probe set according to claim 9, wherein, a primer pair targeting the Pseudomonas aeruginosa has a nucleotide sequence selected from a group consisting of SEQ ID NO:37-38; a primer pair targeting the Escherichia coli has a nucleotide sequence selected from a group consisting of SEQ ID NO:39-40;a primer pair targeting the Klebsiella pneumoniae has a nucleotide sequence selected from a group consisting of SEQ ID NO:41-42;a primer pair targeting the Acinetobacter baumannii has a nucleotide sequence selected from a group consisting of SEQ ID NO:43-44;a primer pair targeting the Staphylococcus aureus has a nucleotide sequence selected from a group consisting of SEQ ID NO:45-46;a primer pair targeting the Enterococcus faecium has a nucleotide sequence selected from a group consisting of SEQ ID NO:47-48;a primer pair targeting the Enterococcus faecalis has a nucleotide sequence selected from a group consisting of SEQ ID NO:49-50;a primer pair targeting the Enterobacter cloacae has a nucleotide sequence selected from a group consisting of SEQ ID NO:51-52;a primer pair targeting the Candida albicans has a nucleotide sequence selected from a group consisting of SEQ ID NO:53-54;a primer pair targeting the Candida glabrata has a nucleotide sequence selected from a group consisting of SEQ ID NO:55-56;a primer pair targeting the Candida parapsilosis has a nucleotide sequence selected from a group consisting of SEQ ID NO:57-58;a primer pair targeting the Candida tropicalis has a nucleotide sequence selected from a group consisting of SEQ ID NO:59-60;a primer pair targeting the carbapenem resistant KPC gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:61-62;a primer pair targeting the carbapenem resistant NDM gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:63-64;a primer pair targeting the carbapenem resistant OXA48 gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:65-66;a primer pair targeting the carbapenem resistant IMP gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:67-68;a primer pair targeting the vancomycin resistant vanA gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:69-70;a primer pair targeting the vancomycin resistant vanB gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:71-72;a primer pair targeting the vancomycin resistant vanM gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:73-74;a primer pair targeting the methicillin resistant mecA gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:75-76; and, a primer pair targeting the methicillin resistant mecC gene has a nucleotide sequence selected from a group consisting of SEQ ID NO:77-78.

11. A kit, comprising one selected from a group consisting of the universal probe described in claim 1 or a primer-probe set for detecting one selected from a group consisting of a pathogenic microorganism and a resistant gene, and an auxiliary agent or a carrier, wherein the primer-probe set for detecting one selected from a group consisting of a pathogenic microorganism and a resistant gene comprises the universal probe according to claim 1, a specific primer pair and a single-modified fluorescence-free probe, and the specific primer pair targets the pathogenic microorganism and the resistant gene.